Advancing CKD and Cardiovascular Risk Management Through Diagnostic Testing - Episode 10
Guiding CKD Treatment Decisions with uACR and eGFR Trends
Learn how KDIGO risk staging and urine ACR guide CKD management, triage, and timely nephrology referral when red flags appear.
This episode, titled, ‘Guiding CKD Treatment Decisions with uACR and eGFR Trends,’ features panelists discussing the following critical questions:
- How are uACR and eGFR trends used to guide treatment decisions in patients with early-stage versus advanced CKD?
- When do you refer to a nephrologist?
Led by the moderator, the panel discusses the evolving role of the nephrologist in 2026, shifting from a focus on end-stage dialysis to a strategic partnership in managing advanced disease. Dr. Beavers explains that due to specialist capacity and access constraints, clinicians should prioritize referrals for patients transitioning into the high-risk "orange and red" segments of the KDIGO heat map (typically around an eGFR of 30). This tiered approach allows primary care and other specialists to utilize the expanded therapeutic armamentarium for early-stage patients, thereby preserving renal function and maintaining eligibility for other comorbid treatments.
The conversation also identifies specific "red flags" that necessitate early specialist consultation regardless of staging, such as an outsized degree of proteinuria, a lack of traditional risk factors like hypertension or diabetes, or a significant family history suggesting the need for a biopsy. By clearly defining these referral triggers, the panel aims to reduce patient frustration and prevent "dropped balls" in care. Ultimately, the experts advocate for a model where common pathways into kidney disease are managed through a broad cardiorenal metabolic lens, reserving specialized nephrology resources for diagnostic complexity and late-stage progression.
In the next episode, ‘Approaches to Prioritizing and Sequencing Therapies in CKD,’ panelists will continue their discussion on chronic kidney disease and highlight the transition to a "four-pillar" treatment model for CKD—comprising RAS inhibitors, SGLT2 inhibitors, non-steroidal MRAs, and GLP-1 receptor agonists—emphasizing that the clinical focus must shift from simple diagnosis to aggressive dose titration. They advocate for a multidisciplinary approach to manage this complex polypharmacy, leveraging pharmacists for medication titration and utilizing clear, goal-oriented communication to improve patient adherence and health literacy.
